143 related articles for article (PubMed ID: 22580497)
21. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir.
Bernstein DI; Stanberry LR; Harrison CJ; Kappes JC; Myers MG
J Gen Virol; 1986 Aug; 67 ( Pt 8)():1601-12. PubMed ID: 3016155
[TBL] [Abstract][Full Text] [Related]
22. Three-dimensional analysis of combination effect of ellagitannins and acyclovir on herpes simplex virus types 1 and 2.
Vilhelmova N; Jacquet R; Quideau S; Stoyanova A; Galabov AS
Antiviral Res; 2011 Feb; 89(2):174-81. PubMed ID: 21134403
[TBL] [Abstract][Full Text] [Related]
23. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice.
Kern ER; Richards JT; Overall JC; Glasgow LA
Antiviral Res; 1983 Nov; 3(4):253-67. PubMed ID: 6320718
[TBL] [Abstract][Full Text] [Related]
24. Acyclovir resistant genital herpes virus infection in a patient with AIDS.
Marrero M; Alvarez M; Millan JC; Mas Lago P; Soler M; Diaz M
Acta Virol; 1991 Jan; 35(1):86-9. PubMed ID: 1683121
[TBL] [Abstract][Full Text] [Related]
25. [The synergistic antiviral effect of acyclovir and ribavirin against the herpes simplex type-1 virus and the pseudorabies virus in vitro].
Shishkov S; Pancheva S
Acta Microbiol Bulg; 1990; 25():69-75. PubMed ID: 2166426
[TBL] [Abstract][Full Text] [Related]
26. Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice.
Shestakov A; Jenssen H; Hancock RE; Nordström I; Eriksson K
Antiviral Res; 2013 Nov; 100(2):455-9. PubMed ID: 24012999
[TBL] [Abstract][Full Text] [Related]
27. [Combined action of nucleosides and alpha-interferon in inhibiting the reproduction of the herpes simplex type-II virus].
Temicheva EV; Malinovskaia VV; Manakhova LS; Mironova LL; Galegov GA
Biull Eksp Biol Med; 1987 Oct; 104(10):490-2. PubMed ID: 2823929
[TBL] [Abstract][Full Text] [Related]
28. Ellagitannins as synergists of ACV on the replication of ACV-resistant strains of HSV 1 and 2.
Vilhelmova-Ilieva N; Jacquet R; Quideau S; Galabov AS
Antiviral Res; 2014 Oct; 110():104-14. PubMed ID: 25111906
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
30. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.
Liu WG; Chen ZJ; Song JZ; Ma ZX
Antimicrob Agents Chemother; 1986 Feb; 29(2):278-80. PubMed ID: 2424367
[TBL] [Abstract][Full Text] [Related]
31. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antiherpes virus activity of acyclovir and interferon in human corneal stromal cells.
Taylor JL; Casey MS; O'Brien WJ
Invest Ophthalmol Vis Sci; 1989 Mar; 30(3):365-70. PubMed ID: 2466806
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Spector T; Averett DR; Nelson DJ; Lambe CU; Morrison RW; St Clair MH; Furman PA
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4254-7. PubMed ID: 2987969
[TBL] [Abstract][Full Text] [Related]
34. Peptide inhibitors against herpes simplex virus infections.
Galdiero S; Falanga A; Tarallo R; Russo L; Galdiero E; Cantisani M; Morelli G; Galdiero M
J Pept Sci; 2013 Mar; 19(3):148-58. PubMed ID: 23389903
[TBL] [Abstract][Full Text] [Related]
35. Combined effects of acyclovir and human interferon-alpha on herpes simplex virus replication in cultured neural cells.
Hanada N; Kido S; Kuzushima K; Goto Y; Rahman MM; Morishima T
J Med Virol; 1989 Sep; 29(1):7-12. PubMed ID: 2555447
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs.
Bravo FJ; Stanberry LR; Kier AB; Vogt PE; Kern ER
Antiviral Res; 1993 May; 21(1):59-72. PubMed ID: 8391249
[TBL] [Abstract][Full Text] [Related]
37. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
39. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
40. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
